Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Long-Term Investments of $894.7 million for Q1 2026, up 186.46% year-over-year from $312.3 million in Q1 2025, and up 16.02% quarter-over-quarter from $771.2 million in Q4 2025.
Kymera Therapeutics (KYMR) Long-Term Investments (2020 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Long-Term Investments for 7 consecutive years, with $894.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments rose 186.46% year-over-year to $894.7 million; the TTM figure through Mar 2026 stood at $894.7 million (up 186.46% YoY), while the FY2025 annual figure was $771.2 million, up 112.91% from the prior year.
- Long-Term Investments rose to $894.7 million in Q1 2026 per KYMR's latest filing, from $771.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $894.7 million in Q1 2026 and bottomed at $61.4 million in Q1 2023.
- Historically, Long-Term Investments has averaged $273.7 million across 5 years, with a median of $192.4 million in 2024.
- Annual changes were most pronounced in 2023 — Long-Term Investments slumped 59.67% — and 2024, when it jumped 489.58%.
- Kymera Therapeutics' Long-Term Investments stood at $152.3 million in 2022, then tumbled by 59.67% to $61.4 million in 2023, then surged by 489.58% to $362.2 million in 2024, then surged by 112.91% to $771.2 million in 2025, then grew by 16.02% to $894.7 million in 2026.
- Business Quant data shows KYMR's Long-Term Investments at $894.7 million in Q1 2026, $771.2 million in Q4 2025, and $473.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 813.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 813.90 Mn |
| Mar 31, 2026 | 894.70 Mn |
| Dec 31, 2025 | 771.16 Mn |
| Sep 30, 2025 | 473.06 Mn |
| Jun 30, 2025 | 297.63 Mn |
| Mar 31, 2025 | 312.34 Mn |
| Dec 31, 2024 | 362.20 Mn |
| Sep 30, 2024 | 361.00 Mn |
| Jun 30, 2024 | 192.45 Mn |
| Mar 31, 2024 | 224.39 Mn |
| Dec 31, 2023 | 61.43 Mn |
| Sep 30, 2023 | 76.99 Mn |
| Jun 30, 2023 | 104.76 Mn |
| Mar 31, 2023 | 61.40 Mn |
| Dec 31, 2022 | 152.33 Mn |
| Sep 30, 2022 | 113.70 Mn |
| Jun 30, 2022 | 90.20 Mn |
| Mar 31, 2022 | 102.50 Mn |
| Dec 31, 2021 | 125.20 Mn |
| Sep 30, 2021 | 74.70 Mn |